Radium-223 demonstrates increased antitumor activity in combination with 177Lu-PSMA-617 in the intratibial LNCaP xenograft model of bone metastatic prostate cancer

被引：1
|
作者：
Scholz, Arne
Knuuttila, Matias
Zdrojewska, Justyna
Suominen, Mari I.
Alhoniemi, Esa
Schatz, Christoph A.
Zitzmann-Kolbe, Sabine
Kakonen, Sanna-Maria
Hagemann, Urs B.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-5043
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5043
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Establishing 177Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer
    Fendler, Wolfgang P.
    Stuparu, Andreea D.
    Evans-Axelsson, Susan
    Luckerath, Katharina
    Wei, Liu
    Kim, Woosuk
    Poddar, Soumya
    Said, Jonathan
    Radu, Caius G.
    Eiber, Matthias
    Czernin, Johannes
    Slavik, Roger
    Herrmann, Ken
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (11) : 1786 - 1792
  • [22] AlphaBet: Combination of Radium-223 and [177Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol)
    Kostos, Louise
    Buteau, James P.
    Yeung, Theresa
    Iulio, Juliana Di
    Xie, Jing
    Cardin, Anthony
    Chin, Kwang Y.
    Emmerson, Brittany
    Owen, Katie L.
    Parker, Belinda S.
    Fettke, Heidi
    Furic, Luc
    Azad, Arun A.
    Hofman, Michael S.
    FRONTIERS IN MEDICINE, 2022, 9
  • [23] Combination of Proton Irradiation and Targeted Radionuclide Therapy with 177Lu-PSMA-617 in a Tumor Mouse Model of Prostate Cancer
    Mueller, C.
    Perrin, R.
    Umbricht, C.
    van der Meulen, N.
    Safai, S.
    Weber, D.
    Lomax, A.
    Schibli, R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S180 - S181
  • [24] Effect of 177Lu-PSMA-617 radioligand therapy on quality of life in patients with advanced metastatic prostate cancer
    Scheer, C.
    Juptner, M.
    Zhao, Y.
    Zuhayra, M.
    Lutzen, U.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S130 - S130
  • [25] Salivary gland dosimetry in therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617
    Happel, C.
    Voeller, L.
    Kranert, W. T.
    Baumgarten, J.
    Groener, D.
    Gruenwald, F.
    Sabet, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S102 - S102
  • [26] Metastatic Prostate Cancer With Restored Hormone-Response After Radioligand Therapy With 177Lu-PSMA-617
    Schlenkhoff, Carl Diedrich
    Knuepfer, Eberhard
    Essler, Markus
    Ahmadzadehfar, Hojjat
    CLINICAL NUCLEAR MEDICINE, 2016, 41 (07) : 572 - 573
  • [27] Promising 177Lu-PSMA-617 Therapy Results in Patients with Metastatic Castration-Resistant Prostate Cancer
    Brnjic, Antonio
    Frye, Sarah
    Botkin, Crystal
    Osman, Medhat
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62
  • [28] Combined 177Lu-PSMA-617 PRLT and abiraterone acetate versus 177Lu-PSMA-617 PRLT monotherapy in metastatic castration-resistant prostate cancer: An observational study comparing the response and durability
    Suman, Sonam
    Parghane, Rahul V.
    Joshi, Amit
    Prabhash, Kumar
    Talole, Sanjay
    Basu, Sandip
    PROSTATE, 2021, 81 (15): : 1225 - 1234
  • [29] Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617
    Ferdinandus, Justin
    Eppard, Elisabeth
    Gaertner, Florian C.
    Kuerpig, Stefan
    Fimmers, Rolf
    Yordanova, Anna
    Hauser, Stefan
    Feldmann, Georg
    Essler, Markus
    Ahmadzadehfar, Hojjat
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (02) : 312 - 319
  • [30] Hematotoxicity after radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617
    Zimbelmann, Stefanie
    Eppard, Elisabeth
    Hauser, Stefan
    Kuerpig, Stefan
    Yordanova, Anna
    Essler, Markus
    Ahmadzadehfar, Hojjat
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
12345